{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-017328","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.236048+00:00","generated_at":"2026-05-17T04:27:45.894957+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bioAffinity reports Q3 CyPath® Lung test sales up 95% QoQ, 97% YTD","bullets":["CyPath® Lung test sales in Q3 2025 increased 95% over Q2 2025; nine-month sales up 97% vs same period 2024.","Growth driven by adoption at Veterans’ hospitals and market expansion in the mid-Atlantic region.","New patients using CyPath® Lung rose 77% in Q3; patient compliance for at-home sample collection improved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-017328","json":"https://secwatch.observer/filing/0001493152-25-017328.json","markdown":"https://secwatch.observer/filing/0001493152-25-017328.md","text":"https://secwatch.observer/filing/0001493152-25-017328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/0001493152-25-017328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225017328/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:27:45.894957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}